PDE4 Long-Form Activators for Selective cAMP Signal Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for structurally distinct small molecule activators of PDE4 long forms for therapeutic applications, as no such activators have been reported in clinical development, and existing activators are limited in diversity.
Innovation Solution
Development of novel compounds, represented by Formulas I to V, which selectively activate PDE4 long forms, offering potential therapeutic benefits by reducing excessive intracellular cAMP signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If small molecule activators of PDE4 long forms are developed for therapeutic applications, then therapeutic benefits are achieved by reducing excessive intracellular cAMP signaling, but structural diversity and variety of such activators are currently limited
Solution Approach 1:
The patent segments the PDE4 enzyme family into distinct long forms (PDE4A, PDE4B, PDE4C, PDE4D) with unique structural characteristics, and develops compounds that selectively target each subtype. This segmentation approach allows for structure-specific activator design, increasing structural diversity while maintaining reliable therapeutic effects through selective activation of appropriate PDE4 long form isoforms for different disease indications
Solution Approach 2:
The patent introduces local quality variations in the small molecule structures by modifying specific regions of the molecules to interact with distinct features of different PDE4 long form isoforms. This includes varying functional groups, ring structures, and molecular conformations at specific locations within the compounds, enabling selective binding and activation while maintaining overall structural diversity across the compound series
2Adaptability or versatility
If new compounds are developed to activate PDE4 long forms, then therapeutic options are expanded, but complexity of compound structure and synthesis increases
Solution Approach 1:
The patent designs a core molecular scaffold that serves as a universal platform for PDE4 long form activation across multiple disease indications. This multi-functional core structure can be systematically modified with different substituents to create diverse compounds for different therapeutic applications, thereby expanding therapeutic options without proportionally increasing structural complexity. The universal scaffold approach allows for efficient structure-activity relationship studies and streamlined synthesis across the compound series
Solution Approach 2:
The patent employs parameter changes in the molecular structures by systematically varying specific chemical parameters such as substituent types, ring sizes, and functional group positions on the core scaffold. These controlled parameter modifications enable the generation of structurally diverse compounds with tailored properties for different therapeutic indications, while maintaining manageable complexity through systematic variation rather than radical structural redesign
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate selective activation of PDE4 long forms, providing therapeutic benefits in treating or preventing diseases mediated by excessive cAMP signaling, including conditions like ADPKD, with potential for cost-effective pharmaceutical formulation.
Implementation Method 1
A proposed negative allosteric modulation of PDE4 long forms by small molecules has been reported
Implementation Method 2
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5'-AMP
Implementation Method 3
The intracellular concentration of cAMP is controlled by the relative balance between its rate of production and degradation
Data Source
AI summary
The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).